×

Important Information

This section of the website (the “Microsite”) of Mereo BioPharma Group plc (the “Company”) has been prepared solely for your information and for the purpose of providing background information on the Company, its business, the upcoming general meeting of the Company’s shareholders, and the industry in which the Company operates or any particular aspect thereof. For further information, please see the shareholder circular published by the Company in connection with the General Meeting which is available at www.mereobiopharma.com/GeneralMeeting2022 or at sec.gov.

The information contained in the Microsite has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in the Microsite and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in the Microsite is subject to verification, correction, completion and change without notice. In making available the Microsite, none of the Company or any of its subsidiaries, or any of any such person’s directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update the information contained in the Microsite or to provide the recipient with access to any additional information that may arise in connection with it. Accordingly, undue reliance should not be placed on any of the data contained in the Microsite.

Forward-Looking Statements

The Microsite and the information in it contain “forward-looking statements.” All statements other than statements of historical fact are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements relate to future events, including, but not limited to, statements regarding future clinical development, efficacy, safety and therapeutic potential of clinical product candidates, including expectations as to reporting of data, conduct and timing and potential future clinical activity and milestones and expectations regarding the initiation, design and reporting of data from clinical trials. Forward-looking statements are often identified by the words “believe,” “expect,” “anticipate,” “plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,” “estimate,” “outlook” and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company’s current expectations, beliefs and assumptions concerning future developments and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of its latest Annual Report on Form 20-F, reports on Form 6-K and other documents furnished or filed from time to time by the Company with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. The Microsite and the information in it also contain estimates, projections and other information concerning the Company’s business and the markets for the Company’s product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events, or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources.

OK

Who we are

Our vision

Driven by a true understanding of the critical nature of our mission, we harness the power of science, with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders, to create new possibilities for patients who need them. We do this in a focused and capital efficient manner.
MEREO(HR)1264

How we work

We operate with the utmost efficiency to maximize our resources and speed up development. We are agile, so we can quickly and easily respond to both challenges and opportunities. And we are innovative and brave, with the courage to explore new frontiers in the pursuit of new possibilities for patients.

quote
Every single person within the Mereo ecosystem has a mission-critical role to play, whether they’re an employee, partner, patient or investor.”
Lindsey Talking 4 Denise

Our history

Mereo BioPharma (Mereo) was founded in March 2015 to fund and develop high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired a portfolio of three product candidates from Novartis in July 2015 and a fourth product from AstraZeneca in October 2017. In April 2019, Mereo merged with OncoMed, a Nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing novel oncology products. Thanks to this merger, we have been able to strengthen the balance sheet, broaden our shareholder base and further diversity our product portfolio, adding two additional clinical stage oncology programs to our pipeline.

MG 8230

Our team

The Mereo team is a crew on a mission. We understand the gravity of our work for patients with few therapeutic options, and that as such, there is no room for passengers.

Every single team member is here because of their passion for helping patients and their unique skills, experience and perspectives. Mereo’s inclusive, collaborative culture ensures that we can all thrive and fulfil our potential.

Our Leadership

We are led by a highly passionate senior management team with established track record in late-stage clinical development, and extensive experience in pharmaceutical and biotechnology companies.

Our board

Our Board includes members who have held executive leadership positions within the biopharmaceutical and biotechnology industries. Our Board brings with them diverse and complimentary skill sets.

Join us on our mission

image

We are always looking for individuals that want to make a difference. We welcome and consider applications to join our team. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment).  If you are interested in working in a collaboratively driven environment and building a career with Mereo please send an updated CV and covering letter to jointheteam@mereobiopharma.com 

image
Who We Are Images Governance 2

Our corporate governance and social responsibility

Good corporate governance is a central element of the successful growth and development of the Company. The Board and its Committees play a key role in the Company’s governance by seeking to ensure that an effective system of internal controls and risk management procedures is in place.

Case studies

Subscribe to our email alerts

View our privacy notice

close

Subscribe

* indicates required
Alert Types

We respect your privacy and do not sell, rent or loan any identifiable information collected on this site. Any information that you give us will be treated with the utmost care and security and according to current data protection legislation. It will not be used in ways to which you have not consented. Please review our privacy policy before providing any information and select the YES option button to consent receiving the selected information.

image

image